259-gene NGS assay for hematologic malignancies

• Detects SNVs, Indels, CNVs, and rearrangements

• Designed to predict responses to immunotherapies and targeted therapies

• Measures critical biomarkers in B-cell malignancies

• Multiple sample types acceptable for testing

Features and benefits

Low Input of Predicine Assays

Low sample input

High Sensitivity Predicine

Ultra-high sensitivity

Specimen flexibility

Actionable results and data interpretation

Sample types

Whole blood
Bone marrow aspirate 

Sample requirements

2-5 mL plasma
4-10 mL blood
0.2-0.4 mL bone marrow aspirate

Turnaround time

8 days

*CLIA-certified assay requires two tubes of 10 mL whole blood

Characterize genomic footprint and monitor disease progression in blood cancers

PredicineHEME™ is a 259 gene assay that targets known mutations associated with B-cell malignancies including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL). The assay can help guide decisions for immunotherapy, targeted therapy and relevant clinical trials for blood cancers.  It is currently used in clinical research. 


PredicineHeme for Blood Cancers


Available in RUO and CLIA-validated assay


We offer pilot program grants to select biopharma and academic partners to empower translational research and clinical studies. To initiate a study, contact us via the form below.

Contact us

If you have any questions or need assistance, complete this form and we will respond within 24 hours.